Please assess the completion status of the following clinical trial:

Trial Title: Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologically proven solid tumour malignancy~* Age \>= 18 years~* Karnofsky performance status \>= 70~* \>= 4 brain metastases, all eligible to be treated with radiosurgery~* All brain metastases \<= 4.0 cm in any diameter~* Pre-treatment contrast enhanced MRI brain \<= 42 days prior to enrollment~* Patient able to provide his/her own written informed consent~Exclusion Criteria:~* Prior radiosurgery, whole brain radiotherapy, or cranial radiotherapy~* Previous surgical resection of brain metastasis (biopsy is allowed)~* Prior chemotherapy ≤ 7 days prior to enrollment~* Planned chemotherapy during radiosurgery~* Leukemia, lymphoma, germ-cell tumour, small-cell lung cancer diagnosis~* Brainstem metastasis~* Leptomeningeal metastases~* Contraindication to MR imaging with contrast~* Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brain metastases (>= 4) (Type: None): Patients with pathologically proven solid tumour malignancy who have \>=4 brain metastases will be treated with gamma knife radiosurgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).